Devita, Hellman, and Rosenberg's Cancer

LWBK1006-33 LWW-Govindan-Review November 24, 2011 11:25

462 DeVita, Hellman, and Rosenberg’s CANCER: Principles and Practice of Oncology Review

Finally, defects in the bone marrow microenvironment, such as defective

or reduced growth of stromal progenitors, are thought to play a role.

Answer 33.8. The answer is D.

High-dose chemotherapy and allogeneic HSCT are the only known cura-

tive therapy in MDS. It is indicated at presentation in patients with high-

risk MDS, who have a matched sibling donor. In lower risk disease, it

may be considered at the time of progression. It is the treatment of choice

for pediatric MDS; however, Fanconi anemia should be excluded prior to

transplant, with diepoxybutane testing.